Single-Dose Drug Development Candidate for Schistosomiasis

Aryl hydantoins were identified in the early 1980s as a promising antischistosomal chemotype. However, as exemplified by Ro 13-3978, this compound series produced antiandrogenic side effects on the host, a not unexpected outcome given their structural similarity to the antiandrogenic drug nilutamide. The two key advances in our optimization of Ro 13-3978 were swapping the aryl trifluoromethyl substituent with a difluoroethyl to abolish antiandrogenic effects and replacing the hydrogen atoms of the <i>gem</i>-dimethyl substructure with deuterium atoms to increase metabolic stability. Combining these two structural changes led to the discovery of single-dose drug candidate AR102, a compound with potent, selective, and broad-spectrum activity against schistosomes, a long pharmacokinetic half-life in preclinical species, and an acceptable safety profile.

Authors

Institutions

Publication Details

Journal
ACS Infectious Diseases
Published
2024-10-18
DOI
https://doi.org/10.1021/acsinfecdis.4c00677
Citations
3
Primary Topic
Parasites and Host Interactions
Type
article
Field-Weighted Citation Impact
1.55

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Single-Dose Drug Development Candidate for Schistosomiasis

Jeremy O. Jones, Jonathan L. Vennerstrom, Michael J. Campbell, Cécile Häberli et al.
3 citations
ACS Infectious Diseases
Parasites and Host Interactions
1.55
article

Single-Dose Drug Development Candidate for Schistosomiasis

Jeremy O. Jones, Jonathan L. Vennerstrom, Michael J. Campbell, Cécile Häberli, Kasiram Katneni, Derek A. Leas, David M. Shackleford, Yuxiang Dong, Andrew J. Neville, Paul H. Davis, Susan A. Charman, Thomas T. Schulze, Rahul Patil, Gong Chen, Xiaofang Wang, Thao Pham, Jennifer Keiser, Meiyu Hu
article en
3 citations

Abstract

Aryl hydantoins were identified in the early 1980s as a promising antischistosomal chemotype. However, as exemplified by Ro 13-3978, this compound series produced antiandrogenic side effects on the host, a not unexpected outcome given their structural similarity to the antiandrogenic drug nilutamide. The two key advances in our optimization of Ro 13-3978 were swapping the aryl trifluoromethyl substituent with a difluoroethyl to abolish antiandrogenic effects and replacing the hydrogen atoms of the <i>gem</i>-dimethyl substructure with deuterium atoms to increase metabolic stability. Combining these two structural changes led to the discovery of single-dose drug candidate AR102, a compound with potent, selective, and broad-spectrum activity against schistosomes, a long pharmacokinetic half-life in preclinical species, and an acceptable safety profile.

ACS Infectious DiseasesVol. 10(11)
University of Nebraska at Omaha (US), City Of Hope National Medical Center (US), Nebraska Medical Center (US), Swiss Tropical and Public Health Institute (CH), University of Basel (CH), Bipar (FR), Monash University (AU), University of Nebraska Medical Center (US)
Nebraska Space Grant Consortium, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
Zero hunger
Openalex Percentile: Top 18%
Parasites and Host Interactions
1.55
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.